Wave Life Sciences: Regained WVE-006 Ownership and Platform Validation Support Buy Rating and $33 Target

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Wave Life Sciences. The associated price target remains the same with $33.00.

Yun Zhong has given his Buy rating due to a combination of factors that strengthen the investment case for Wave Life Sciences. By regaining full ownership of WVE-006 for alpha-1 antitrypsin deficiency from GSK, Wave can now independently control development strategy and timelines, which the analyst believes will allow the program to advance more efficiently. In addition, the positive clinical data from WVE-006 is viewed as a key proof point for Wave’s in vivo RNA editing platform, supporting not only this asset but also follow-on candidates such as WVE-008 and other AIMer programs that target larger market opportunities.

Furthermore, Zhong views the recent regulatory feedback received by Beam Therapeutics for its BEAM-302 program in the same indication as a constructive precedent that suggests Wave could similarly pursue an accelerated approval pathway based on AAT biomarker endpoints. Expected upcoming data from the 400mg multidose cohort in early 2026 may show stronger editing activity and further validate the efficacy and dosing profile of WVE-006, while the safety profile to date appears supportive of continued dose escalation to 600mg. Taken together, these clinical, regulatory, and platform-validation dynamics underpin Zhong’s confidence in Wave’s long-term value and justify maintaining a $33 price target alongside a Buy rating.